Deviating from safety guidelines during deferiprone therapy in clinical practice may not be associated with higher risk of agranulocytosis

Autor:	Usama El-Safy, M. Akif Yesilipek, Yousryeia Abdel Rahman, Zakaria Al Hawsawi, Youssef Al-Tonbary, Ghazi Al Damanhouri, Shebl Said Shebl, Fernando Tricta, Yurdanur Kilinç, Mostafa A.S Salama, Zeynep Karakas, Mohamad H. Qari, Mohamed M. Badr, M Elalfy, Anne Stilman, Dilek Yazman, Noemi Toiber Temin, Yasser Wali
Rok vydání:	2013
Předmět:	Pediatrics medicine.medical_specialty Blood transfusion Package insert business.industry medicine.medical_treatment Thalassemia Hematology Neutropenia medicine.disease chemistry.chemical_compound Oncology chemistry hemic and lymphatic diseases Pediatrics Perinatology and Child Health Absolute neutrophil count Medicine Young adult Deferiprone business Prospective cohort study
Zdroj:	Pediatric Blood & Cancer. 61:879-884
ISSN:	1545-5009
DOI:	10.1002/pbc.24920
Popis:	Background A risk associated with the iron chelator deferiprone is the development of neutropenia or agranulocytosis. Accordingly, the product label recommends weekly blood monitoring and immediate interruption of treatment upon detection of an absolute neutrophil count (ANC)
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::b0551706f0054578fe85dc27e7f3194b https://doi.org/10.1002/pbc.24920 Zobrazit plný text záznamu Plný text